Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Adam, Shutes"'
Autor:
Timothy Guzi, Nancy E. Kohl, Christoph Lengauer, Christopher Winter, Adam Shutes, Natasja Brooijmans, Brian Hodous, Joseph L. Kim, Neil Bifulco, Nicolas Stransky, Weifan Weng, Nooreen Rubin, Michael Sheets, Chandra Miduturu, Margit Hagel
Supplementary Figure S1. Potency against FGFR family and kinome selectivity. Supplementary Figure S2. Kinases with a cysteine at the equivalent position to Cys552 in FGFR4. Supplementary Figure S3. MALDI Mass Spectrometry of FGFR4. Supplementary Figu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8961190ae57361a2b45e2b8293c97f7
https://doi.org/10.1158/2159-8290.22530420
https://doi.org/10.1158/2159-8290.22530420
Autor:
Timothy Guzi, Nancy E. Kohl, Christoph Lengauer, Christopher Winter, Adam Shutes, Natasja Brooijmans, Brian Hodous, Joseph L. Kim, Neil Bifulco, Nicolas Stransky, Weifan Weng, Nooreen Rubin, Michael Sheets, Chandra Miduturu, Margit Hagel
Supplementary Methods and Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0bdbee434896ada0f2bffee6775eee2
https://doi.org/10.1158/2159-8290.22530417
https://doi.org/10.1158/2159-8290.22530417
Autor:
Dusica Cvetinovic Santos, Klaus Urbahns, Simone C. Zimmerli, Andreas Goutopoulos, Justin R. Potnick, Andrew Bender, Michael Meyring, Adam Shutes, Christopher Charles Victor Jones, Jared Head, Ben C. Askew, Bayard R. Huck, Ansgar Wegener, Hui Qiu, Theresa L. Johnson, Nadia Brugger, Sherer Brian A, Ngan Nguyen, Mohanraj Dhanabal, Ralf Schmidt, Roland Grenningloh, Reinaldo Jones, Richard D. Caldwell, Ariele Viacava Follis, Brian Healey, Montserrat Camps, Igor Mochalkin, Federica Morandi, Lesley Liu-Bujalski, Vikram Dutt, Brian L. Hodous, Anna Gardberg, Thomas Eichhorn
Publikováno v:
Journal of Medicinal Chemistry. 62:7643-7655
Bruton's tyrosine kinase (BTK) inhibitors such as ibrutinib hold a prominent role in the treatment of B cell malignancies. However, further refinement is needed to this class of agents, particularly in terms of adverse events (potentially driven by k
Autor:
Darshan S. Sappal, Vivek Kadambi, Riadh Lobbardi, Joseph L. Kim, Adam Shutes, Michael Palmer, Nicolas Stransky, Robert M. Campbell, Richard Woessner, Timothy LaBranche, Klaus P. Hoeflich, Neil Bifulco, Andrew P. Garner, Grace O. Silva, Erin O’Hearn, Kevin J. Wilson, Timothy J. Guzi, Stefanie Schalm, Marion Dorsch, Lucian DiPietro, Stephen D. Miller, Christoph Lengauer
Publikováno v:
Molecular Cancer Therapeutics. 18:B127-B127
Introduction: Fibrolamellar Carcinoma (FLC) is a rare primary liver malignancy, affecting children and young adults without chronic liver disease. FLC tumors are largely resistant to chemotherapy, making the identification of effective treatment opti
Autor:
Joseph L. Kim, Oleg Schmidt-Kittler, Yemarshet K. Gebreyohannes, Timothy Guzi, Kevin J. Wilson, Alison J. Davis, Alexandra K. Gardino, Adam Shutes, Christoph Lengauer, Lucian DiPietro, Stephen D. Miller, Brian L. Hodous, Yulian Zhang, Doug Wilson, Timothy LaBranche, Nicholas Lydon, Michael Heinrich, Nancy Kohl, Patrick Schöffski, Natasja Brooijmans, Agnieszka Wozniak, Erica Evans, Xing Julia Zhu, Daniel J. DeAngelo, Andy Boral, Beni B. Wolf
Publikováno v:
Science Translational Medicine. 9
Targeting oncogenic kinase drivers with small-molecule inhibitors can have marked therapeutic benefit, especially when administered to an appropriate genomically defined patient population. Cancer genomics and mechanistic studies have revealed that h
Autor:
Erica K, Evans, Alexandra K, Gardino, Joseph L, Kim, Brian L, Hodous, Adam, Shutes, Alison, Davis, Xing Julia, Zhu, Oleg, Schmidt-Kittler, Doug, Wilson, Kevin, Wilson, Lucian, DiPietro, Yulian, Zhang, Natasja, Brooijmans, Timothy P, LaBranche, Agnieszka, Wozniak, Yemarshet K, Gebreyohannes, Patrick, Schöffski, Michael C, Heinrich, Daniel J, DeAngelo, Stephen, Miller, Beni, Wolf, Nancy, Kohl, Timothy, Guzi, Nicholas, Lydon, Andy, Boral, Christoph, Lengauer
Publikováno v:
Science translational medicine. 9(414)
Targeting oncogenic kinase drivers with small-molecule inhibitors can have marked therapeutic benefit, especially when administered to an appropriate genomically defined patient population. Cancer genomics and mechanistic studies have revealed that h
Autor:
Channing J. Der, Adam Shutes, Emily J. Chenette, Carolyn Weinbaum, Janice E. Buss, Audrey Minden, Adrienne D. Cox, Anastacia C. Berzat
Publikováno v:
Journal of Biological Chemistry. 280:33055-33065
Wrch-1 is a Rho family GTPase that shares strong sequence and functional similarity with Cdc42. Like Cdc42, Wrch-1 can promote anchorage-independent growth transformation. We determined that activated Wrch-1 also promoted anchorage-dependent growth t
Publikováno v:
Current Biology. 14:2052-2056
Rho family GTPases are GDP/GTP-regulated molecular switches that regulate signaling pathways controlling diverse cellular processes [1, 2, 3]. Wrch-1 was identified as a Wnt-1 regulated Cdc42 homolog, upregulated by Wnt1 signaling in Wnt1-transformed
Autor:
Miller B. Jones, Adam Shutes, Randall J. Kimple, Francis S. Willard, Benjamin R. Yerxa, David P. Siderovski
Publikováno v:
Combinatorial Chemistry & High Throughput Screening. 6:399-407
Heterotrimeric G-proteins are molecular switches that couple serpentine receptors to intracellular effector pathways and the regulation of cell physiology. Ligand-bound receptors cause G-protein alpha subunits to bind guanosine 5'-triphosphate (GTP)
Publikováno v:
Biochemistry. 41:3828-3835
Novel guanine nucleotide analogues have been used to investigate the role of Mg(2+) in nucleotide release and binding with the small G protein rac. The fluorescent analogues have 7-(ethylamino)-8-bromocoumarin-3-carboxylic acid attached to the 3'-pos